目的:探讨胸腺肽α1(Thymosin alpha 1,Tα1)对肝细胞癌(hepatocellular carcinoma,HCC)患者根治性手术预后的影响。方法:回顾性分析本院2007年1月至2012年12月558例HCC根治性手术后患者,分为Tα1治疗组146例和空白对照组412例,经倾向性评分匹配后,比较两组术后肝功能恢复情况、无瘤生存率和总生存率。结果:两组患者共106对匹配成功,中位随访时间为22个月,治疗组较对照组术后TBIL、ALB、ALT、PT等肝功能指标明显改善(P<0.05)。治疗组和对照组术后1、2、3年无瘤生存率分别为79.7%、70.8%、67.3%和69.9%、61.5%、51.6%(P=0.019);总生存率分别为87.2%、82.0%、68.4%和78.2%、64.2%、%Objective: The effect of thymosin alpha 1 (Tα1) on patients with hepatocellular carcinoma (HCC) after radical hepatectomy was assessed. Methods: A total of 558 HCC patients treated by radical hepatectomy were retrospectively collected. Patients in the treatment group (n=146) received postoperative Tα1 therapy, whereas patients in the control group (n=412) did not. Propensity scale matching was conducted to improve the balance between the two groups. Changes in liver function, recurrence-free survival rates, and overall survival rates were compared between the two groups. Results: Postoperative liver function (i.e., TBIL, ALB, ALT, and PT) in the treatment group was significantly better than that in the control group (P<0.05). The one-, two-, and three-year recurrence-free survival rates and overall survival rates in the treatment group were significantly higher than those in the control group (P=0.019 and P=0.011, respectively). Conclusion:Postoperative Tα1 therapy can improve postoperative liver function, thus significantly prolonging recurrence-free survival and overall survival.
展开▼